Atara Biotherapeutics (ATRA) vs Black Diamond Therapeutics (BDTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Black Diamond Therapeutics (BDTX) over the past year, losing 53.7% versus a loss of 65.5%. Over five years, BDTX leads with a -79.3% price change compared with -98.6% for ATRA. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $64.5 million), about 1.2 times the size.
Black Diamond Therapeutics converts more of its revenue into profit, with a net margin of 32.0% versus 27.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | BDTX |
|---|---|---|
| Share price | $6.33 | $1.31 |
| Market cap | $64.49M | $75.28M |
| 1-day change | -0.16% | -5.76% |
| YTD return | -65.01% | -46.09% |
| 1-year return | -53.73% | -65.53% |
| 5-year return | -98.56% | -79.30% |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | $70.00M |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $32.69M | $22.37M |
| Operating margin | 29.69% | 17.89% |
| Net margin | 27.07% | 31.95% |
| 52-week high | $19.15 | $3.97 |
| 52-week low | $3.92 | $1.31 |
| Distance from 52-week high | -66.94% | -67.00% |
| Analyst consensus | buy | none |
| Avg. price target upside | +115.96% | +663.36% |
| Average volume | 35.46K | 697.70K |
| Shares outstanding | 10.19M | 57.47M |
| Employees | 10 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed BDTX by 11.8 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
ATRA vs BDTX FAQ
Which is bigger, Atara Biotherapeutics or Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $64.49M for Atara Biotherapeutics (ATRA).
Which stock has performed better over the past year, ATRA or BDTX?
ATRA returned -53.73% over the past 12 months, compared with -65.53% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Black Diamond Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.